HER2 breast cancer therapies: a review
Conleth G Murphy, Shanu ModiBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been...
Enregistré dans:
Auteurs principaux: | Conleth G Murphy, Shanu Modi |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3a73e9c2eef24772a3f1de13accb894c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Bevacizumab in the treatment of HER2-negative breast cancer
par: Vito Lorusso
Publié: (2008) -
Current neoadjuvant treatment options for HER2 positive breast cancer
par: Abdel-Razeq H, et autres
Publié: (2011) -
Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
par: Bella Kaufman, et autres
Publié: (2008) -
Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer
par: Sun JZ, et autres
Publié: (2014) -
Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer
par: Thomas Kunzke, et autres
Publié: (2021)